Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. 

Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals with obesity respond differently to food cues than those in normal-weight individuals, making the neuroreceptors a prime target for obesity treatments and therapy
News | SNMMI
Molecular Imaging Identifies Brain Changes in Response to Food Cues; Offers Insight into Obesity Interventions

June 28, 2023 — Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals ...

Time June 28, 2023
arrow
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach
News | SNMMI
Novel Theranostic Agent Targets Multiple Cancer Types

June 28, 2023 — A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake ...

Time June 28, 2023
arrow
A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI)
News | SNMMI
Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

June 28, 2023 — A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese ...

Time June 28, 2023
arrow
News | SNMMI
Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

June 27, 2023 — Helen Nadel, MD, FRCPC, director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at ...

Time June 27, 2023
arrow
Contrast-enhanced mammography (CEM) is an emerging modality combining digital mammography with the administration of a contrast agent
News | Contrast Media
FDA approves Bayer’s Ultravist (iopromide) Injection for Contrast-enhanced Mammography

June 26, 2023 — Bayer announced that Ultravist (iopromide)-300, -370, its iodine-based contrast agent, has been approved ...

Time June 26, 2023
arrow
Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.
News | SNMMI
Nizar A. Mullani Receives SNMMI 2023 Georg Charles de Hevesy Nuclear Pioneer Award

June 26, 2023 — Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has ...

Time June 26, 2023
arrow
Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for Precision Imaging, and associate chair for imaging sciences in the Department of Radiology at Massachusetts General Hospital and professor of radiology at Harvard Medical School in Boston, Massachusetts, has been named as the first recipient of the new Minoshima-Pappas Transformational Leadership Award.
News | SNMMI
Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

June 26, 2023 — Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for ...

Time June 26, 2023
arrow
News | SNMMI
Study on Value of 68Ga-FAPI PET/CT Imaging for Evaluation of Disease Activity in Rheumatoid Arthritis presented during SNMMI 2023

June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease ...

Time June 26, 2023
arrow
During its 2023 Annual Meeting, the Image of the Year was selected by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and represents research presented which reports on the ability of a novel theranostic pair to successfully detect metastatic pancreatic cancer and provide a means of selecting appropriate treatments.
News | SNMMI
Image of the Year and Research Announced at SNMMI 2023 on Theranostic Pair for Early Detection and Effective Treatment of Pancreatic Cancer

June 26, 2023 — A first-in-human evaluation of the novel theranostic pair 68Ga-DOTA-5G / 177Lu-DOTA-ABM-5G has confirmed ...

Time June 26, 2023
arrow
A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated
News | SNMMI
Translational PET Tracer Visualizes Brain Cholesterol Metabolism

June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol ...

Time June 25, 2023
arrow
Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College in Phoenix, Arizona, and nuclear medicine technologist at Banner Staffing Services in Tucson, Arizona, has been elected 2023-24 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS)
News | SNMMI
SNMMI Announces Julie Dawn Bolin, MS, CNMT, as President-Elect of the Technologist Section During 2023 Annual Meeting

June 25, 2023 — Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College ...

Time June 25, 2023
arrow
News | SNMMI
Ultra-High Resolution Brain PET Scanner Visualizes and Quantifies Brainstem Nuclei for the First Time

June 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously ...

Time June 24, 2023
arrow
 A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.
News | SNMMI
New Whole-Body PET Technology Offers Cost-Effective Solution to Improve Image Resolution and Sensitivity

June 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has ...

Time June 24, 2023
arrow
Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on radiotherapies and theranostics readiness at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting.
News | SNMMI
Cardinal Health Highlights Nuctrac Theranostic Module, Theranostics Readiness at SNMMI 2023

June 23, 2023 — Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on ...

Time June 23, 2023
arrow
Therapeutically equivalent and fully substitutable to Kinevac (Sincalide for Injection) formulated, filled and packaged in the United States provides health care facilities with choice and value
News | Contrast Media
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection

June 21, 2023 — Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the ...

Time June 21, 2023
arrow
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023
News | Prostate Cancer
Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 21, 2023
arrow
Planned transition part of NorthStar’s strategy for continued growth and industry leadership in domestic radioisotope production and radiopharmaceutical development to meet needs of patients, pharmaceutical companies and radiopharmacies
News | Radiopharmaceuticals and Tracers
NorthStar Medical Technologies, LLC Appoints Frank Scholz, PhD, as President and Chief Executive Officer

June 19, 2023 — NorthStar Medical Technologies, LLC, a global innovator in the development, production and ...

Time June 19, 2023
arrow
The first patient has been scanned in a Phase I clinical trial for an investigational fluorine-18 (18F) CD8-targeted imaging radiopharmaceutical
News | Radiopharmaceuticals and Tracers
First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

June 15, 2023 — With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare ...

Time June 15, 2023
arrow
A type of artificial intelligence (AI), Deep Learning (DL) technology can advance medical imaging capabilities by providing more robust, accurate, and data-driven information as well as support more efficient workflows and exams
News | Artificial Intelligence
GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

May 31, 2023 — GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning ...

Time May 31, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now